Phase 2Completed

Therapy With an Oxytocin Adjunct for Major Depression (TOAD2015)

Combined Use of Intranasal Oxytocin and Interpersonal Psychotherapy for the Treatment of Major Depressive Disorder (MDD): A Randomized Controlled Trial

Sponsor
Concordia University, Montreal (Academic or other)
Enrollment
24 enrolled
Conditions
Depressive Disorder
Interventions
Oxytocin nasal spray or placebo
Ages
adults
Registry
NCT02405715

Full record on ClinicalTrials.gov

From the registry

This study evaluates the addition of intranasal oxytocin to the treatment of Major Depression using interpersonal psychotherapy. Half of the participants will receive a placebo adjunct to interpersonal psychotherapy, and the other half will receive oxytocin.

Primary outcomes

  • Diagnostic status: Major Depressive Episode Using The SCID-IV [Change Score]
  • Depressive symptoms (clinician-rated) 9Hamilton Rating Scale for Depression (HRS-D)[Change Score]
  • Depressive symptoms (clinician-rated) Inventory for Depressive Symptomology (IDS-C) [Change Score]
  • Stress and social functioning (Global Axis of Functioning using the SCID-IV (GAF) [Change Score]

History

  1. Last registry update

  2. Primary completion

  3. Registered

  4. Started

Papers citing this trial